Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis

Footnotes

This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.

Conflict of interest: Dr. Nanzer reports personal fees from Astra-Zeneca, personal fees from Napp, outside the submitted work.

Conflict of interest: Dr. Dhariwal has nothing to disclose.

Conflict of interest: Dr. Kavanagh has nothing to disclose.

Conflict of interest: Dr. Hearn has nothing to disclose.

Conflict of interest: Dr. Fernandes has nothing to disclose.

Conflict of interest: Dr. Thomson has nothing to disclose.

Conflict of interest: Dr. Roxas has nothing to disclose.

Conflict of interest: Dr. Green has nothing to disclose.

Conflict of interest: Dr Agarwal has nothing to disclose.

Conflict of interest: Dr. Kent reports personal fees from Astra-Zeneca, personal fees from GSK, outside the submitted work.

Conflict of interest: Dr. Jackson reports personal fees from Astra-Zeneca, personal fees from GSK, personal fees from Teva, personal fees from Sanofi, personal fees from Novartis, outside the submitted work.

Conflict of interest: Dr. D'Ancona reports personal fees from Chiesi, personal fees from Astra Zeneca, personal fees from GSK, personal fees from Napp, outside the submitted work.